An Overview of BIOBEAT19

The BIOBEAT19 summit brought together an international lineup of speakers and panelists drawn from the commercial, academic and public sectors to explore the UK’s advantage and opportunities in this fast-growing field.

Emma Walmsley, CEO, GSK delivered the keynote address, followed by leading women in the sector examining the journey from science to patients and what value means for different people and organisations. UCL was represented by Professor Emma Morris who chaired the panel discussing the translational journey from Innovation to scale up of Cell and Gene therapy. 

The emphasis was on sustaining and building the UK’s excellence in the advanced therapy area and the urgent need to address the skills gap and to provide training at all stages from innovative manufacture to pharmacy and clinical delivery. Further key challenges highlighted were GMP manufacture to support early academic led clinic trials, reducing large scale manufacture costs and the affordability of delivering therapies in the NHS. 

Biobeat have also published their 2019 ‘50 Movers and Shakers in Biobusiness’ which includes Dr Maryam Atakhorrami, former member of UCL TRO and current COO, London-Health Data Research UK.